Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure
NCT ID: NCT07064720
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
60 participants
INTERVENTIONAL
2024-07-12
2026-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine on Brain Injury Patients
NCT06661980
Neuroprotective Effect of Dexomitomidine
NCT05487742
Normothermia in Patients With Acute Cerebral Damage
NCT00491192
Prevention of Low Blood Pressure in Persons With Tetraplegia
NCT00237770
Mechanisms of Cerebrovascular Control
NCT02936687
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group (D)
Dexmedetomidine with Mannitol
Dexmedetomidine with Mannitol
receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
Group (M)
Mannitol only
Mannitol (20%)
receive 0.5 g/kg of mannitol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine with Mannitol
receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
Mannitol (20%)
receive 0.5 g/kg of mannitol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cardiac patients
* Cerebrovascular disease
* Glaucoma
* Hepatic failure
* Renal failure
* History of anaphylactic reaction to dexmedetomidine or mannitol
* Hemodynamic instability
* Cannot measure ONSD for example due to ophthalmological problems.
* Any cause of preoperative increase in ICP for example intracranial space occupying lesions.
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Samir Wahdan
Assistant Professor of anesthesia, SICU & and pain management
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
facility of medicine Cairo university
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-50-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.